ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2026
Impact of rapid molecular testing on clinical outcomes for methicillin-susceptible
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rapid molecular blood culture identification (BCID) enables earlier pathogen identification and targeted antibiotic therapy compared with traditional culture-based methods. Methicillin-susceptible Methods: This retrospective, single-center, quasi-experimental program evaluation included adult patients with monomicrobial MSSA bacteremia. Patients were grouped based on identification by BCID or conventional culture-based methods. Automatic Infectious Diseases consultation was performed for all patients. The primary outcome was a desirability of outcome ranking incorporating treatment success, acute kidney injury (AKI), and inpatient mortality. Secondary outcomes included time-to-optimal therapy, duration of bacteremia, treatment success, and hospital length of stay. Results: A total of 300 patients were included (150 per cohort). BCID use was associated with earlier MSSA identification (0.8 vs 2.1 days; Conclusions: Incorporation of rapid BCID into an established automatic Infectious Diseases consultation program improved outcomes in MSSA bacteremia by facilitating earlier β-lactam therapy and reducing nephrotoxicity. Antimicrobial stewardship programs should prioritize rapid diagnostics to optimize MSSA management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.